Rha-PEG3-SMCC
Rha-PEG3-SMCC (compound 13) is a agent-linker conjugate for ADC with potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3.
For research use only. We do not sell to patients.
- CAS No.: 2794904-62-2
- Formula: C24H38N2O10
- Molecular Weight:514.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Drug-Linker Conjugates for ADC Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Traditional Cytotoxic Agents |
Chemical Information
-
CAS No. 2794904-62-2
-
Molecular Weight 514.57
-
Formula C24H38N2O10
-
SMILES
O=C(C1CCC(CC1)CN2C(C=CC2=O)=O)NCCOCCOCCO[C@H]3[C@@H]([C@@H]([C@H]([C@@H](O3)C)O)O)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)